26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 28 / Drugs : 48 - (DrugBank : 28) / Drug target genes : 38 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01343355 (ClinicalTrials.gov) | January 2011 | 25/4/2011 | Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | HTLV-I-Associated Myelopathy | Drug: Tamibarotene | St. Marianna University School of Medicine | NULL | Active, not recruiting | 30 Years | 75 Years | Both | 15 | Phase 2/Phase 3 | Japan |